

INOVIO BIOMEDICAL CORP  
Form 8-K  
March 16, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported):** **March 16, 2007**

**Inovio Biomedical Corporation**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**11494 Sorrento Valley Road, San Diego,  
California**

(Address of principal executive offices)

**001-14888**

(Commission  
File Number)

**33-0969592**

(I.R.S. Employer  
Identification No.)

**92121-1318**

(Zip Code)

**Registrant's telephone number, including area code:** **(858) 597-6006**

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Edgar Filing: INOVIO BIOMEDICAL CORP - Form 8-K

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) On March 16, 2007, Robert Goodenow, Ph. D., registrant's Vice President, Corporate Development and a named executive officer, resigned.

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 16, 2007

INOVIO BIOMEDICAL CORPORATION

By:                   /s/                   PETER KIES  
Peter Kies, Chief Financial Officer

3

---